Jane Street Group, LLC Neurocrine Biosciences Inc Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

A detailed history of Jane Street Group, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Jane Street Group, LLC holds 24,516 shares of NBIX stock, worth $3.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,516

Previous 110,558 77.83%

Holding current value

$3.02 Million

Previous $15.2 Million 81.46%

% of portfolio

0.0%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $9.86 Million - $13.2 Million	-86,042 Reduced 77.83%	24,516 $2.82 Million
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $18.5 Million - $20.3 Million	-141,446 Reduced 56.13%	110,558 $15.2 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $31.1 Million - $34.2 Million	238,124 Added 1715.59%	252,004 $34.8 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $7.84 Million - $9.82 Million	-73,958 Reduced 84.2%	13,880 $1.83 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $2.98 Million - $3.71 Million	31,683 Added 56.42%	87,838 $9.88 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $767,898 - $899,469	-8,577 Reduced 13.25%	56,155 $5.3 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $4.2 Million - $5.49 Million	44,617 Added 221.81%	64,732 $6.55 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $11.8 Million - $14 Million	-110,298 Reduced 84.58%	20,115 $2.4 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $7.6 Million - $8.9 Million	82,597 Added 172.74%	130,413 $13.9 Million
Q2 2022 Aug 16, 2022	SELL	$75.79 - $100.07 $6.36 Million - $8.4 Million	-83,943 Reduced 63.71%	47,816 $4.66 Million
Q1 2022 May 17, 2022	SELL	$72.45 - $94.81 $3.58 Million - $4.68 Million	-49,408 Reduced 27.27%	131,759 $12.4 Million
Q4 2021 Feb 15, 2022	BUY	$79.65 - $106.22 $3.98 Million - $5.31 Million	49,957 Added 38.07%	181,167 $15.4 Million
Q3 2021 Nov 16, 2021	BUY	$86.18 - $99.03 $9 Million - $10.3 Million	104,441 Added 390.16%	131,210 $12.6 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $2.82 Million - $3.22 Million	-31,478 Reduced 54.04%	26,769 $2.61 Million
Q1 2021 May 18, 2021	SELL	$87.57 - $119.4 $972,552 - $1.33 Million	-11,106 Reduced 16.01%	58,247 $5.67 Million
Q4 2020 Feb 17, 2021	SELL	$86.91 - $108.33 $329,041 - $410,137	-3,786 Reduced 5.18%	69,353 $6.65 Million
Q3 2020 Nov 17, 2020	BUY	$96.16 - $135.15 $2.06 Million - $2.9 Million	21,446 Added 41.49%	73,139 $7.03 Million
Q2 2020 Aug 17, 2020	BUY	$85.09 - $130.36 $3.66 Million - $5.6 Million	42,979 Added 493.22%	51,693 $6.31 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $194,009 - $293,842	2,583 Added 42.13%	8,714 $755,000
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $9,634 - $13,161	111 Added 1.84%	6,131 $659,000
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $4,693 - $5,684	-56 Reduced 0.92%	6,020 $542,000
Q2 2019 Aug 15, 2019	BUY	$72.24 - $91.27 $168,969 - $213,480	2,339 Added 62.59%	6,076 $513,000
Q1 2019 May 16, 2019	SELL	$69.31 - $91.53 $155,531 - $205,393	-2,244 Reduced 37.52%	3,737 $329,000
Q4 2018 Feb 15, 2019	SELL	$68.32 - $124.36 $1.2 Million - $2.18 Million	-17,552 Reduced 74.58%	5,981 $427,000
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $2.05 Million - $2.61 Million	20,763 Added 749.57%	23,533 $2.89 Million
Q2 2018 Aug 15, 2018	SELL	$75.3 - $105.99 $1.28 Million - $1.8 Million	-16,963 Reduced 85.96%	2,770 $272,000
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $1.02 Million - $1.24 Million	13,462 Added 214.67%	19,733 $1.64 Million
Q4 2017 Feb 15, 2018	SELL	$58.53 - $77.59 $598,644 - $793,590	-10,228 Reduced 61.99%	6,271 $487,000
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $791,457 - $1.01 Million	16,499	16,499 $1.01 Million

Others Institutions Holding NBIX

# of Institutions

624

Shares Held

94.2M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.8B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Neurocrine Biosciences Inc Transaction History